SK Biopharm Signs Pharmaceutical Contract Worth 10.3 Billion KRW with Subsidiary

[Asia Economy Reporter Hwang Yoon-joo] SK Biopharm announced on the 21st that it has signed a pharmaceutical supply contract worth 10,380,620,000 KRW with its subsidiary SK Life Science. This accounts for 39.93% of recent sales revenue. The contract period is from March 21, 2022, to June 30, 2022.